Effects of Drug-Polymer Interactions on Tablet Properties During the Development of Abuse-Deterrent Dosage Forms
- 67 Downloads
The objective of the present study is to understand the effects of drug-PEO interactions during the thermal treatment of polyethylene oxide (PEO)-based, directly compressed, abuse-deterrent formulations (ADFs). The drugs studied were dextromethorphan HBr monohydrate, ketoprofen, promethazine HCl, and anhydrous theophylline. Thermal treatment above the melting point of PEO resulted in tablets with higher crushing strength (> 500 N). It was observed that drug-PEO interactions during thermal treatment (80°C) led to solubilization of the incorporated drug. Drugs with higher solubility in the molten PEO, when added at higher weight fractions, interfered with the process of tablet densification which led to an increase in tablet dimensions and created defects in the fused matrix. These changes resulted in the formation of a more porous matrix. Thermal treatment led to a decrease in PEO crystallinity. The decreased crystallinity led to differences in the hydration and dissolution properties of the PEO. The change in dissolution properties of PEO accompanied with the dimensional and microstructural changes resulted in a greater drug release for some of the studied drugs. In conclusion, although thermal treatment above the melting point of PEO is an efficient manufacturing process in imparting crush-resistant features, drug-PEO interactions during the thermal treatment and the impact of thermal treatment on the properties of formulation components may impact tablet properties and lead to potential performance differences.
KEY WORDSabuse-deterrent formulations (ADFs) polyethylene oxide (PEO) thermal treatment drug-PEO interactions tablet properties and drug release
- 12.Royce AE. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms. United States Patent US. 1993; 5,273,758.Google Scholar
- 16.Rahman Z, Yang Y, Korang-Yeboah M, Siddiqui A, Xu X, Ashraf M, et al. Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations. Int J Pharm. 2016;502(1–2):138–50. https://doi.org/10.1016/j.ijpharm.2016.02.029.CrossRefPubMedGoogle Scholar
- 17.Upadhye SB, Properties R-SAR. Applications of polyethylene oxide and Ethylcellulose for tamper resistance and controlled drug delivery. In: Repka MA, Langley N, DiNunzio J, editors. Melt extrusion: materials, technology and drug product design. New York, NY: Springer New York; 2013. p. 145–58.CrossRefGoogle Scholar
- 18.Storrow AB, Magoon MR, Norton J. The dextromethorphan defense: dextromethorphan and the opioid screen. Acad Emerg Med. 1995;2(9):791–4. https://doi.org/10.1111/j.1553-2712.1995.tb03273.x.CrossRefPubMedGoogle Scholar
- 19.Dextromethorphan HBr solubility. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000ChemR.pdf. Accessed 14 Sept 2018.
- 20.Dextromethorphan HBr melting point. Available from: https://www.scbt.com/scbt/product/dextromethorphan-hydrobromide-125-69-9. Accessed 14 Sept 2018.
- 21.Ketoprofen solubility and melting point. Available from: National Center for Biotechnology Information. PubChem Compound Database; CID=3825, https://pubchem.ncbi.nlm.nih.gov/compound/3825. Accessed 14 Sept 2018.
- 22.Promethazine HCl solubility. Available from: http://www.selleckchem.com/datasheet/promethazine-hcl-DataSheet.html. Accessed 14 Sept 2018.
- 23.Promethazine HCl melting point. Available from: National Center for Biotechnology Information. PubChem Compound Database; CID=6014, https://pubchem.ncbi.nlm.nih.gov/compound/6014. Accessed 2 Oct 2018.
- 24.Theophylline solubility and melting point. Available from: National Center for Biotechnology Information. PubChem Compound Database; CID=2153, https://pubchem.ncbi.nlm.nih.gov/compound/2153. Accessed 14 Sept 2018.
- 25.Dextromethorphan HBr decomposition temperature. Available from: https://www.spectrumchemical.com/MSDS/D3100.pdf. Accessed 14 Sept 2018.
- 31.Consultation documents. Dextromethorphani hydrobromidum. Dextromethorphan HBr decomposition temperature. Available from: World Health Organization. https://www.who.int/medicines/areas/quality_safety/quality_assurance/2014-05-23Revision_DextromethorphanHBr-QAS14-585_22052014.pdf. Accessed 14 Sept 2018.
- 34.Malaj L, Censi R, Mozzicafreddo M, Pellegrino L, Angeletti M, Gobetto R, et al. Influence of relative humidity on the interaction between different aryl propionic acid derivatives and poly (vinylpyrrolydone) K30: evaluation of the effect on drug bioavailability. Int J Pharm. 2010;398(1–2):61–72. https://doi.org/10.1016/j.ijpharm.2010.07.024.CrossRefPubMedGoogle Scholar
- 37.Boyce H, Smith D, Byrn S, Saluja B, Qu W, Gurvich VJ, et al. In vitro assessment of nasal insufflation of comminuted drug products designed as abuse deterrent using the vertical diffusion cell. AAPS PharmSciTech. 2018;19(4):1744–57. https://doi.org/10.1208/s12249-017-0947-2.CrossRefPubMedGoogle Scholar
- 42.Bhattacharjya S, Wurster DE. Investigation of the drug release and surface morphological Properties of film-coated pellets, and physical, thermal and mechanical Properties of free films as a function of various curing conditions. AAPS PharmSciTech. 2008;9(2):449–57. https://doi.org/10.1208/s12249-008-9058-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Van Renterghem J, Dhondt H, Verstraete G, De Bruyne M, Vervaet C, De Beer T. The impact of the injection mold temperature upon polymer crystallization and resulting drug release from immediate and sustained release tablets. Int J Pharm. 2018;541(1–2):108–16. https://doi.org/10.1016/j.ijpharm.2018.01.053.CrossRefPubMedGoogle Scholar
- 48.Shojaee S, Nokhodchi A, Maniruzzaman M. Evaluation of the drug solubility and rush ageing on drug release performance of various model drugs from the modified release polyethylene oxide matrix tablets. Drug Deliv Transl Res. 2017;7(1):111–24. https://doi.org/10.1007/s13346-016-0344-5.CrossRefPubMedGoogle Scholar